VivoSeq
Other

MRI

0

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

MRI is an early-stage landscape with 0 programs across 3 companies. The most active players are Bayer, Tonix Pharmaceuticals, Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

74/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalT

Tonix Pharmaceuticals, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed14 · 61%
Recruiting4 · 17%
Terminated3 · 13%
Withdrawn2 · 9%

Clinical Trials

Trial Activity

23 trials

Investigational MRI Clinical Software and Hardware
Recruiting·NNorthwestern University·Phase 4·NCT05215132·2,000 enrolled
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT02421380·109 enrolled
Hyperpolarized 129Xe MRI Lung Health Cohort
Recruiting·UUniversity of Kansas Medical Center·N/A·NCT05766384·260 enrolled
Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
Recruiting·UUniversity of Virginia·Phase 1/2·NCT03331302·30 enrolled
Tamoxifen-MRI Study
Completed·UUniversity of Pennsylvania·Phase 2·NCT00295100·78 enrolled
Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI
Completed·PPhoenix Children's Hospital·N/A·NCT03023566·250 enrolled
Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT
Completed·—·Phase 4·NCT01471145·40 enrolled
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
Completed·UUniversity of California, Irvine·Phase 3·NCT01979679·28 enrolled
Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Completed·Bayer logoBayer·Phase 4·NCT00764387·166 enrolled
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 4·NCT00176592·75 enrolled
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Completed·GGuerbet·Phase 4·NCT00650845·135 enrolled
Eovist vs. Dotarem Healthy Volunteer MRI
Completed·—·Phase 4·NCT02431598·44 enrolled
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN
Completed·YYale University·Phase 1·NCT03341715·18 enrolled
Repeatability in Hyperpolarized 3-Helium With MRI
Completed·—·Phase 4·NCT03776747·18 enrolled
Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
Completed·TTonix Pharmaceuticals, Inc.·Phase 1·NCT03443960·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)